EMFAT
NKTR icon

Emerald Mutual Fund Advisers Trust’s Nektar Therapeutics NKTR Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.4M Buy
256,106
+2,981
+1% +$170K 0.89% 41
2025
Q4 		$10.7M Buy
253,125
+19,920
+9% +$1.11M 0.52% 86
2025
Q3 		$13.3M Buy
+233,205
New +$7.72M 0.69% 59

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's NKTR Position: Q1 2026 in Review

Emerald Mutual Fund Advisers Trust increased its Nektar Therapeutics (NKTR) stake by 1.2% in Q1 2026, buying an estimated $170K and bringing the position to 256,106 shares worth $18.4M. The position accounts for 0.89% of the portfolio, ranked #41.

Emerald Mutual Fund Advisers Trust first reported a position in NKTR in Q3 2025 and has held it in 3 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Emerald Mutual Fund Advisers Trust held 256,106 shares of Nektar Therapeutics worth $18.4M as of Q1 2026.
  • Emerald Mutual Fund Advisers Trust bought 2,981 Nektar Therapeutics shares in Q1 2026, an estimated $170K.
  • Nektar Therapeutics made up 0.89% of Emerald Mutual Fund Advisers Trust's portfolio in Q1 2026, its #41 holding.
  • Emerald Mutual Fund Advisers Trust first reported a position in Nektar Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q1 2026, filed 4 May 2026.